SABS
SAB Biotherapeutics, Inc.
$3.98
+$0.17 (+4.61%)Today
Key Statistics
Market cap303.94M
Price-Earnings ratio-4.05
Dividend yield—
Average volume1.96M
High today$3.99
Low today$3.70
Open price$3.80
Volume280.05K
52 Week high$6.60
52 Week low$1.67
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.